Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Biniam Adane"'
Autor:
Giovanny Hernandez, Taylor S. Mills, Jennifer L. Rabe, James S. Chavez, Susan Kuldanek, Gregory Kirkpatrick, Leila Noetzli, Widian K. Jubair, Michelle Zanche, Jason R. Myers, Brett M. Stevens, Courtney J. Fleenor, Biniam Adane, Charles A. Dinarello, John Ashton, Craig T. Jordan, Jorge Di Paola, James R. Hagman, V. Michael Holers, Kristine A. Kuhn, Eric M. Pietras
Publikováno v:
Haematologica, Vol 105, Iss 3 (2020)
Rheumatoid arthritis (RA) is a debilitating autoimmune disease characterized by chronic inflammation and progressive destruction of joint tissue. It is also characterized by aberrant blood phenotypes including anemia and suppressed lymphopoiesis that
Externí odkaz:
https://doaj.org/article/eca59744a0444860b5057f8bf06972fb
Autor:
Biniam Adane, Haobin Ye, Nabilah Khan, Shanshan Pei, Mohammad Minhajuddin, Brett M. Stevens, Courtney L. Jones, Angelo D’Alessandro, Julie A. Reisz, Vadym Zaberezhnyy, Maura Gasparetto, Tzu-Chieh Ho, Kathleen K. Kelly, Jason R. Myers, John M. Ashton, Julie Siegenthaler, Tsutomu Kume, Eric L. Campbell, Daniel A. Pollyea, Michael W. Becker, Craig T. Jordan
Publikováno v:
Cell Reports, Vol 27, Iss 1, Pp 238-254.e6 (2019)
Summary: The NADPH-dependent oxidase NOX2 is an important effector of immune cell function, and its activity has been linked to oncogenic signaling. Here, we describe a role for NOX2 in leukemia-initiating stem cell populations (LSCs). In a murine mo
Externí odkaz:
https://doaj.org/article/d5544c2b5ce54bd09d30079612acafba
Autor:
Kimberly Stegmaier, Jérôme Tamburini, Anthony Letai, Mark Wunderlich, Lynn H. Lee, Federica Piccioni, Scott T. Younger, Joseph D. Mancias, Jeremy A. Ryan, Biniam Adane, Sarah Mouche, Thelma Mashaka, Amy Saur Conway, Amanda L. Robichaud, Guillaume Kugener, Caroline S. Wechsler, Miljan Kuljanin, Neekesh V. Dharia, Bo Kyung A. Seong, Nastassja K. Scheidegger, Clément Larrue, Shan Lin
Supplementary Tables from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63a00231f66c2f1f2d618c874e239af4
https://doi.org/10.1158/2159-8290.22540225.v1
https://doi.org/10.1158/2159-8290.22540225.v1
Autor:
Craig T. Jordan, Clayton A. Smith, Michael R. Savona, Haley E. Ramsey, Jonathan A. Gutman, Angelo D'Alessandro, Travis Nemkov, John M. Ashton, Jason R. Myers, Andrew Hammes, Diana Abbott, Jeffrey Schowinsky, Jessica Ponder, Nabilah Khan, Biniam Adane, Courtney L. Jones, Anna Krug, Haobin Ye, Amanda Winters, Anagha Inguva, Maria L. Amaya, James C. Costello, Jihye Kim, Ryan M. Sheridan, Austin E. Gillen, Kent A. Riemondy, Rui Fu, Mohammad Minhajuddin, Brett M. Stevens, Annika Gustafson, Daniel A. Pollyea, Shanshan Pei
Venetoclax-based therapy can induce responses in approximately 70% of older previously untreated patients with acute myeloid leukemia (AML). However, up-front resistance as well as relapse following initial response demonstrates the need for a deeper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::459448356d6d6a3954afc463053a8909
https://doi.org/10.1158/2159-8290.c.6547874.v1
https://doi.org/10.1158/2159-8290.c.6547874.v1
Autor:
Craig T. Jordan, Clayton A. Smith, Michael R. Savona, Haley E. Ramsey, Jonathan A. Gutman, Angelo D'Alessandro, Travis Nemkov, John M. Ashton, Jason R. Myers, Andrew Hammes, Diana Abbott, Jeffrey Schowinsky, Jessica Ponder, Nabilah Khan, Biniam Adane, Courtney L. Jones, Anna Krug, Haobin Ye, Amanda Winters, Anagha Inguva, Maria L. Amaya, James C. Costello, Jihye Kim, Ryan M. Sheridan, Austin E. Gillen, Kent A. Riemondy, Rui Fu, Mohammad Minhajuddin, Brett M. Stevens, Annika Gustafson, Daniel A. Pollyea, Shanshan Pei
Supplementary Figures S1-S5 supporting Main Figures 1-5.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27a46cf40c0c33f9430520efc19df38f
https://doi.org/10.1158/2159-8290.22535510
https://doi.org/10.1158/2159-8290.22535510
Autor:
Kimberly Stegmaier, Jérôme Tamburini, Anthony Letai, Mark Wunderlich, Lynn H. Lee, Federica Piccioni, Scott T. Younger, Joseph D. Mancias, Jeremy A. Ryan, Biniam Adane, Sarah Mouche, Thelma Mashaka, Amy Saur Conway, Amanda L. Robichaud, Guillaume Kugener, Caroline S. Wechsler, Miljan Kuljanin, Neekesh V. Dharia, Bo Kyung A. Seong, Nastassja K. Scheidegger, Clément Larrue, Shan Lin
CRISPR–Cas9-based genetic screens have successfully identified cell type–dependent liabilities in cancer, including acute myeloid leukemia (AML), a devastating hematologic malignancy with poor overall survival. Because most of these screens have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f8b74c36b48f4b32ecfaef81a5921cb
https://doi.org/10.1158/2159-8290.c.6549322
https://doi.org/10.1158/2159-8290.c.6549322
Autor:
Kimberly Stegmaier, Jérôme Tamburini, Anthony Letai, Mark Wunderlich, Lynn H. Lee, Federica Piccioni, Scott T. Younger, Joseph D. Mancias, Jeremy A. Ryan, Biniam Adane, Sarah Mouche, Thelma Mashaka, Amy Saur Conway, Amanda L. Robichaud, Guillaume Kugener, Caroline S. Wechsler, Miljan Kuljanin, Neekesh V. Dharia, Bo Kyung A. Seong, Nastassja K. Scheidegger, Clément Larrue, Shan Lin
Supplementary Data from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91d609241f021048a4e574176ba23569
https://doi.org/10.1158/2159-8290.22540234
https://doi.org/10.1158/2159-8290.22540234
Autor:
Craig T. Jordan, Clayton A. Smith, Michael R. Savona, Haley E. Ramsey, Jonathan A. Gutman, Angelo D'Alessandro, Travis Nemkov, John M. Ashton, Jason R. Myers, Andrew Hammes, Diana Abbott, Jeffrey Schowinsky, Jessica Ponder, Nabilah Khan, Biniam Adane, Courtney L. Jones, Anna Krug, Haobin Ye, Amanda Winters, Anagha Inguva, Maria L. Amaya, James C. Costello, Jihye Kim, Ryan M. Sheridan, Austin E. Gillen, Kent A. Riemondy, Rui Fu, Mohammad Minhajuddin, Brett M. Stevens, Annika Gustafson, Daniel A. Pollyea, Shanshan Pei
Supplementary Tables S1-S6 describing patient characteristics, gene lists, LSC signatures, and reagents.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f6aa26137a69b33270a49fa503428b1
https://doi.org/10.1158/2159-8290.22535507.v1
https://doi.org/10.1158/2159-8290.22535507.v1
Autor:
James DeGregori, Angelo D’Alessandro, Kirk C. Hansen, Craig T. Jordan, Biniam Adane, Sarah Gehrke, Vadym Zaberezhnyy, Hae J. Park, Travis Nemkov, Mark A. Gregory
Purpose:Acute myeloid leukemia (AML) is a hematologic malignancy characterized by the accumulation of immature myeloid precursor cells. AML is poorly responsive to conventional chemotherapy and a diagnosis of AML is usually fatal. More effective and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11f50f1cb7f49b0786b023d0bffbc36a
https://doi.org/10.1158/1078-0432.c.6527879.v1
https://doi.org/10.1158/1078-0432.c.6527879.v1
Autor:
James DeGregori, Angelo D’Alessandro, Kirk C. Hansen, Craig T. Jordan, Biniam Adane, Sarah Gehrke, Vadym Zaberezhnyy, Hae J. Park, Travis Nemkov, Mark A. Gregory
Figure S1. The glutaminase inhibitor CB-839 impairs glutathione metabolism in FLT3WT AML cells. Figure S2. The glutaminase inhibitor CB-839 decreases glutathione levels, but does not increase total cellular ROS levels in AML cells. Figure S3. Antioxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49be6a43542813bd64bae76d97a7a934
https://doi.org/10.1158/1078-0432.22471412.v1
https://doi.org/10.1158/1078-0432.22471412.v1